Brought to you by 
Regulus Therapeutics nets $48.3mm through initial public offering
05 Nov 2012
Executive Summary
Less than two months after filing its S-1, Regulus Therapeutics Inc. (single-stranded oligonucleotide therapeutics) has netted $48.3mm in its initial public offering of 12.9mm shares (including the overallotment) for $4. Last month, the company anticipated selling 4.6mm shares at $10-12.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Regulus Therapeutics nets $48.3mm through initial public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice